Criteria Bio Ventures: Investment Portfolio & Startup News
Criteria Bio Ventures
To add a bio or update investment portfolio click update information.
Investment Portfolio


Cytospire Therapeutics
5 May 2026
Cytospire Therapeutics secures £61m Series A led by 4BIO Capital for cancer therapies that activate the body’s immune cells
Cytospire Therapeutics develops multispecific immune cell engager antibodies designed to enhance and direct the activity of the body’s immune system. Its platform targets gamma delta T cells to generate anti tumour immune responses for patients with cancer and other diseases.


NRG Therapeutics
8 Sept 2025
NRG Therapeutics lands £50m Series B led by SV Health Investors to advance neurodegenerative disease therapies
NRG Therapeutics develops oral small-molecule drugs targeting mitochondrial dysfunction, aiming to slow or halt neurodegenerative diseases such as ALS and Parkinson’s through disease-modifying treatments.
Criteria Bio Ventures
- 1(12 months)
- criteriabioventures.com
More venture news
- 16 Nov 2026

ZyaZya lands a £12m Series A round led by Astanor to turn sugar in food into prebiotic fibre
Series AHealth - 13 Nov 2026

Oyster TherapeuticsOyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases
Series ALife Sciences - 12 Nov 2026

UFORCEUFORCE secures a £530m Series A round led by Valor Equity Partners and UK National Wealth Fund to build uncrewed defence platforms
Series ADefence